$ATRA
Atara Biotherapeutics, Inc.

2020 Q2 Form 10-Q Financial Statement

#000156459020036808 Filed on August 05, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $16.39M $23.28M
YoY Change -29.6% 21.0%
% of Gross Profit
Research & Development $61.56M $52.25M
YoY Change 17.82% 56.5%
% of Gross Profit
Depreciation & Amortization $2.050M $1.740M
YoY Change 17.82% 138.36%
% of Gross Profit
Operating Expenses $77.95M $75.54M
YoY Change 3.2% 43.54%
Operating Profit -$77.95M -$75.54M
YoY Change 3.2% 43.54%
Interest Expense $500.0K $1.210M
YoY Change -58.68% -30.46%
% of Operating Profit
Other Income/Expense, Net $497.0K $1.207M
YoY Change -58.82% -30.75%
Pretax Income -$77.46M -$74.33M
YoY Change 4.21% 46.08%
Income Tax $1.000K $0.00
% Of Pretax Income
Net Earnings -$77.46M -$74.33M
YoY Change 4.21% 46.08%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.139M -$1.601M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $347.7M $190.1M
YoY Change 82.9% -54.41%
Cash & Equivalents $75.91M $59.16M
Short-Term Investments $273.2M $131.0M
Other Short-Term Assets $11.30M $11.00M
YoY Change 2.73% 35.8%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $359.0M $201.1M
YoY Change 78.48% -52.68%
LONG-TERM ASSETS
Property, Plant & Equipment $53.59M $57.09M
YoY Change -6.14% -13.63%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.200M $319.0K
YoY Change 589.66% -80.06%
Total Long-Term Assets $69.10M $73.01M
YoY Change -5.35% 8.0%
TOTAL ASSETS
Total Short-Term Assets $359.0M $201.1M
Total Long-Term Assets $69.10M $73.01M
Total Assets $428.1M $274.1M
YoY Change 56.16% -44.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.100M $6.420M
YoY Change -20.56% -1.23%
Accrued Expenses $20.90M $13.90M
YoY Change 50.36% 16.81%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $400.0K
YoY Change
Total Short-Term Liabilities $31.70M $25.80M
YoY Change 22.85% -5.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $100.0K
YoY Change -100.0%
Other Long-Term Liabilities $15.30M $1.143M
YoY Change 1238.58% -91.21%
Total Long-Term Liabilities $15.30M $1.143M
YoY Change 1238.58% -91.21%
TOTAL LIABILITIES
Total Short-Term Liabilities $31.70M $25.80M
Total Long-Term Liabilities $15.30M $1.143M
Total Liabilities $47.00M $41.87M
YoY Change 12.27% 4.14%
SHAREHOLDERS EQUITY
Retained Earnings -$968.9M -$667.6M
YoY Change 45.13%
Common Stock $899.7M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $381.1M $232.3M
YoY Change
Total Liabilities & Shareholders Equity $428.1M $274.1M
YoY Change 56.16% -44.36%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$77.46M -$74.33M
YoY Change 4.21% 46.08%
Depreciation, Depletion And Amortization $2.050M $1.740M
YoY Change 17.82% 138.36%
Cash From Operating Activities -$56.64M -$54.59M
YoY Change 3.76% 38.41%
INVESTING ACTIVITIES
Capital Expenditures -$2.080M -$730.0K
YoY Change 184.93% -90.2%
Acquisitions
YoY Change
Other Investing Activities -$128.3M $50.99M
YoY Change -351.62% 1328.29%
Cash From Investing Activities -$130.4M $50.25M
YoY Change -359.44% -1398.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 191.3M 7.330M
YoY Change 2509.96% -86.92%
NET CHANGE
Cash From Operating Activities -56.64M -54.59M
Cash From Investing Activities -130.4M 50.25M
Cash From Financing Activities 191.3M 7.330M
Net Change In Cash 4.300M 2.990M
YoY Change 43.81% -76.48%
FREE CASH FLOW
Cash From Operating Activities -$56.64M -$54.59M
Capital Expenditures -$2.080M -$730.0K
Free Cash Flow -$54.56M -$53.86M
YoY Change 1.3% 68.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2012-08-01
CY2019Q1 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
us-gaap:AccountingStandardsUpdate201602Member
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
283934000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-1658000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15201000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-74328000
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
135000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
232279000
us-gaap Profit Loss
ProfitLoss
-150965000
us-gaap Profit Loss
ProfitLoss
-140585000
us-gaap Share Based Compensation
ShareBasedCompensation
26592000
us-gaap Share Based Compensation
ShareBasedCompensation
27470000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4002000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3385000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-170000
atra Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
734000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-93000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
288000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-255000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2933000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2649000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-2049000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-2814000
atra Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
-97000
atra Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
-14071000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-406000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
24172000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
3234000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
4676000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
6670000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
197000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
215272000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75711000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62092000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75905000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60553000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
253000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
338857000
CY2019Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
4575000
CY2019Q1 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
2898000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12269000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-66257000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
378000
CY2019Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
2095000
CY2019Q2 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
1802000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
817000
atra Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
576000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-127000
us-gaap Accretion Expense
AccretionExpense
38000
us-gaap Accretion Expense
AccretionExpense
35000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1423000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-720000
atra Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
0
atra Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-238000
atra Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-535000
atra Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-299000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
541000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-123680000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-124789000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
228224000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
17589000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
140235000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
136876000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3409000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1534000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
96000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1395000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
235000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-165000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5401000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
194000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1539000
atra Finance Lease Assets Obtained In Exchange For Lease Obligations
FinanceLeaseAssetsObtainedInExchangeForLeaseObligations
281000
atra Finance Lease Assets Obtained In Exchange For Lease Obligations
FinanceLeaseAssetsObtainedInExchangeForLeaseObligations
0
atra Non Cash Investing And Financing Activities Accrued Costs Related To Underwritten Public Offering
NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering
322000
atra Non Cash Investing And Financing Activities Accrued Costs Related To Underwritten Public Offering
NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering
0
atra Receivable For Options Exercised
ReceivableForOptionsExercised
0
atra Receivable For Options Exercised
ReceivableForOptionsExercised
24000
us-gaap Interest Paid Net
InterestPaidNet
37000
us-gaap Interest Paid Net
InterestPaidNet
31000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-968900000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions, and judgments that affect the amounts reported in the financial statements and accompanying notes. Significant estimates relied upon in preparing these financial statements include estimates related to clinical trial and other accruals, stock-based compensation expense and income taxes. Actual results could differ materially from those estimates. </p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11917445
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8838236
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
308021000
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
308492000
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
214085000
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
214199000
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
37670000
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
38009000
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
42993000
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
43100000
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
345691000
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
346501000
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
257078000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
257299000
CY2020Q2 us-gaap Interest Receivable
InterestReceivable
800000
CY2019Q4 us-gaap Interest Receivable
InterestReceivable
900000
atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
CY2019 atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
69091000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
65854000
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15504000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11678000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
53587000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
54176000
CY2020Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2100000
CY2019Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1800000
CY2020Q2 atra Due To Licensors Current And Noncurrent
DueToLicensorsCurrentAndNoncurrent
0
CY2019Q4 atra Due To Licensors Current And Noncurrent
DueToLicensorsCurrentAndNoncurrent
0
CY2020Q2 atra Accrued Termination Charges
AccruedTerminationCharges
0
CY2019Q4 atra Accrued Termination Charges
AccruedTerminationCharges
0
CY2020Q2 atra Liabilities Related To Indemnification Agreements
LiabilitiesRelatedToIndemnificationAgreements
0
CY2019Q4 atra Liabilities Related To Indemnification Agreements
LiabilitiesRelatedToIndemnificationAgreements
0
CY2020Q2 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
520000000
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
the exercise price of an option granted to a 10% shareholder cannot be less than 110% of the estimated fair value of the shares on the date of grant. Options granted generally vest over four years and expire in seven to ten years.
atra Shareholder Ownership Percent
ShareholderOwnershipPercent
0.10
CY2020Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
16335544
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13948000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15201000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26592000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
27470000

Files In Submission

Name View Source Status
0001564590-20-036808-index-headers.html Edgar Link pending
0001564590-20-036808-index.html Edgar Link pending
0001564590-20-036808.txt Edgar Link pending
0001564590-20-036808-xbrl.zip Edgar Link pending
atra-10q_20200630.htm Edgar Link pending
atra-10q_20200630_htm.xml Edgar Link completed
atra-20200630.xsd Edgar Link pending
atra-20200630_cal.xml Edgar Link unprocessable
atra-20200630_def.xml Edgar Link unprocessable
atra-20200630_lab.xml Edgar Link unprocessable
atra-20200630_pre.xml Edgar Link unprocessable
atra-ex311_7.htm Edgar Link pending
atra-ex312_6.htm Edgar Link pending
atra-ex321_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending